148
Participants
Start Date
October 4, 2012
Primary Completion Date
October 8, 2014
Study Completion Date
October 8, 2014
Solifenacin succinate suspension
Oral suspension
Site: 6301, Quezon City
Site: 3202, Antwerp
Site: 3209, Antwerp
Site: 3205, Leuven
Site: 5202, Mexico City
Site: 4504, Køge
Site: 4701, Bergen
Site: 3208, Charleroi
Site: 4502, Kolding
Site: 9001, Ankara
Site: 2703, Cape Town
Site: 4501, Aarhus N
Site: 3204, Kortrijk
Site: 3201, Ghent
Site: 3203, Ghent
Site: 4602, Stockholm
Site: 3812, Novi Sad
Site: 9002, Izmir
Site: 4606, Gothenburg
Site: 4603, Skövde
Site: 1006, Shreveport
Site: 4605, Umeå
Site: 8207, Seoul
Site: 8202, Seoul
Site: 8203, Daegu
Site: 5507, Campinas
Site: 5506, Curitiba
Site: 1001, Québec
Site: 4503, Aalborg
Site: 5205, Mexico City
Site: 4805, Gdansk
Site: 4803, Gdansk
Site: 4804, Lubin
Site: 4801, Warsaw
Site: 3810, Belgrade
Site: 8206, Incheon
Site: 3854, Kharkiv
Site: 4403, Leeds
Site: 4401, Sheffield
Astellas Pharma Europe B.V.
INDUSTRY